Department of Neurobiology and Anatomy, Drexel University College of Medicine, Philadelphia, Pennsylvania 19129, USA.
Biol Psychiatry. 2012 Nov 15;72(10):880-8. doi: 10.1016/j.biopsych.2012.04.018. Epub 2012 May 19.
Methylphenidate (MPH) has long been used to treat attention-deficit/hyperactivity disorder (ADHD); however, its cellular mechanisms of action and potential effects on prefrontal cortical circuitry are not well understood, particularly in the developing brain system. A clinically relevant dose range for rodents has been established in the adult animal; however, how this range will translate to juvenile animals has not been established.
Juvenile (postnatal day [PD] 15) and adult (PD90) Sprague Dawley rats were treated with MPH or saline. Whole-cell patch clamp recording was used to examine the neuronal excitability and synaptic transmission in pyramidal neurons of prefrontal cortex. Recovery from MPH treatment was also examined at 1, 5, and 10 weeks following drug cessation.
A dose of 1 mg/kg intraperitoneal MPH, either single dose or chronic treatment (well within the accepted therapeutic range for adults), produced significant depressive effects on pyramidal neurons by increasing hyperpolarization-activated currents in juvenile rat prefrontal cortex, while exerting excitatory effects in adult rats. Minimum clinically-relevant doses (.03 to .3 mg/kg) also produced depressive effects in juvenile rats, in a linear dose-dependent manner. Function recovered within 1 week from chronic 1 mg/kg treatment, chronic treatment with 3 and 9 mg/kg resulted in depression of prefrontal neurons lasting 10 weeks and beyond.
These results suggest that the juvenile prefrontal cortex is supersensitive to methylphenidate, and the accepted therapeutic range for adults is an overshoot. Juvenile treatment with MPH may result in long-lasting, potentially permanent, changes to excitatory neuron function in the prefrontal cortex of juvenile rats.
哌醋甲酯(MPH)长期以来一直被用于治疗注意力缺陷/多动障碍(ADHD);然而,其细胞作用机制及其对前额皮质回路的潜在影响尚不清楚,尤其是在发育中的大脑系统中。在成年动物中已经建立了一个与临床相关的药物剂量范围;然而,这个范围如何转化为幼年动物尚未确定。
使用 MPH 或生理盐水处理幼年(出生后第 15 天[PD])和成年(PD90)Sprague Dawley 大鼠。使用全细胞膜片钳记录来检查前额皮质锥体神经元的神经元兴奋性和突触传递。在停药后 1、5 和 10 周还检查了 MPH 治疗的恢复情况。
1 毫克/千克腹腔内 MPH 的单次剂量或慢性治疗(远在成人接受的治疗范围内),通过增加幼年大鼠前额皮质中超极化激活电流,对锥体神经元产生显著的抑制作用,而对成年大鼠产生兴奋作用。最小的临床相关剂量(0.03 至 0.3 毫克/千克)也以线性剂量依赖性方式对幼年大鼠产生抑制作用。慢性 1 毫克/千克治疗后 1 周内功能恢复,慢性 3 和 9 毫克/千克治疗导致前额神经元抑制持续 10 周及以上。
这些结果表明,幼年前额皮质对哌醋甲酯超敏感,而成年人接受的治疗范围是过度的。幼年时用 MPH 治疗可能导致前额皮质兴奋性神经元功能的长期、潜在永久性改变。